Cytox, a precision medicine company focused on commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s has entered into a research collaboration with Mayo Clinic to test current and develop new proprietary algorithms relating to the diagnosis and prognosis of Alzheimer’s disease. Under the agreement Cytox will assess genetic risk for developing Alzheimer’s disease using its current commercially available approaches developed to run on the
Read More
- Skip to main content
- Skip to secondary menu
- Skip to primary sidebar
- Skip to secondary sidebar
- Skip to footer
Footer
